The nation of Zimbabwe has declined a significant US health deal valued at 367 million US dollars (£272m) spanning five years because of the United States' demand for sensitive data.
This rejection was revealed after a official document from December was disclosed, which showed Head of State Emmerson Mnangagwa believed the agreement was "lopsided".
A government spokesman has since clarified that the US was requesting biological samples for scientific study and commercial purposes while was unwilling to share the benefits from future vaccines.
"We will now turn to the challenging and unfortunate process of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had furnished more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged more negotiations to reach a agreement suitable to both sides so the nation's critical HIV treatment initiative can be sustained.
Wider Background
Zimbabwe's decision comes after a similar situation in Kenya, where a high court halted a related health funding agreement after legal challenges were filed about the safety of Kenyans' health data.
Since resuming office recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
USAID had administered aid for the US government, but Trump stated its expenditure was "wasteful" and his administration was pursuing direct bilateral agreements to enhance transparency and accountability.
According to statements, 16 nations in Africa have to date signed these new health pacts, representing more than $18.3bn in new funding.
Details of the Declined Deal
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this cooperation would have delivered extraordinary benefits for the people of Zimbabwe, especially the 1.2 million currently on antiretroviral therapy via American-funded initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Zimbabwe was being asked to provide its biological resources and data indefinitely, with no equivalent promise of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that shared data," he stated.
"Put simply, our country would supply the raw materials for scientific discovery without any assurance that the resulting innovations would be available to our population if a future health crisis arise."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral deals were upending frameworks already established via the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme created to deal with potential pandemics.
"This system is designed to ensure that when a nation contributes its data, the benefits – including medicines and cures – are shared equitably, not commercialised solely by those with the funds to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We are open to further discussions with our American counterparts on how future co-operation might be designed in a way that honours the independence and dignity of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the government's concerns, but suggested that negotiations must proceed given that much of the country's Aids initiatives relied on external financing.
"In cases where specific concerns exist, including those relating to data governance or implementation frameworks, these can often be resolved through detailed discussion and mutually agreed protections," the group added.
The halted deal underscores the complex challenges between accepting crucial international aid and protecting local interests in an increasingly data-driven world.